Drug given to reduce side effects of pain medication may facilitate gastrointestinal recovery after testicular cancer surgery
Can't see this email? View it online
   
  April 4, 2017  
  Bladder Cancer  
  The latest bladder cancer news from News Medical  
 Drug given to reduce side effects of pain medication may facilitate gastrointestinal recovery after testicular cancer surgeryDrug given to reduce side effects of pain medication may facilitate gastrointestinal recovery after testicular cancer surgery
 
Post-operative recovery and length of hospital stay are critical things to consider when having major surgery. A drug commonly given to reduce the side effects of strong post-surgery pain medications has been found to reduce the length of hospital stays for patients who have undergone major gastrointestinal or bladder cancer procedures.
 
 
 New technique can effectively identify cancer-causing substances in urine or bloodNew technique can effectively identify cancer-causing substances in urine or blood
 
A team of researchers, led by Professor Yoon-Kyoung Cho of Life Science at UNIST has recently developed a new technique that effectively identifies cancer-causing substances in the urine or blood.
 
   Extreme short and long telomeres linked to increased cancer riskExtreme short and long telomeres linked to increased cancer risk
 
The length of the telomere "caps" of DNA that protect the tips of chromosomes may predict cancer risk and be a potential target for future therapeutics, University of Pittsburgh Cancer Institute scientists will report today at the AACR Annual Meeting in Washington, D.C.
 
   OSU scientists find way to fight solid tumors using new cancer-drug delivery systemOSU scientists find way to fight solid tumors using new cancer-drug delivery system
 
A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiation treatment.
 
 Evolution of immuno-oncology
 
Evolution of immuno-oncologyImmuno-oncology did not exist four years ago, it's a term coined by Dr. Axel Hoos, Head of the newly defined immuno-oncology department at GSK. He is also Senior Vice President Therapeutic Area (TA) and Head for Oncology R&D. Previously, it was referred to as cancer immunotherapy, but now it is called immuno-oncology (IO).
 
 
 Study provides insights into how cancer cells can evade FGFR inhibitors
 
Study provides insights into how cancer cells can evade FGFR inhibitorsA new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibitors.